The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

Background: The incidence of non-Hodgkin’s lymphoma (NHL) has increased steadily over the past few decades ... Methods: The up-to-date data on age-standardized incidence and mortality rates of NHL ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Follicular lymphoma is the second most common form of non-Hodgkin lymphoma (NHL), and is ... and it has a five-year survival rate of only 20% for patients in the third line and later.

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

an important new study found that ibrutinib shows some effectiveness in fighting a type of non-Hodgkin lymphoma called mantle cell lymphoma (MCL) though it doesn't increase the overall survival rate ...

17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin ... B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy ...

Anaplastic lymphoma kinase (ALK ... with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non-Hodgkin lymphomas. The function of the full-length ALK receptor is still poorly ...

Background: The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R ...